TDC
IMDZ

Thompson Davis & Co’s Immune Design Corp. IMDZ Stock Holding History

Thompson Davis & Co’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-250
Closed -$1K – 841
2018
Q2 		$1K Hold
250
– – ﹤0.01% 661
2018
Q1 		$1K Hold
250
– – ﹤0.01% 614
2017
Q4 		$1K Hold
250
– – ﹤0.01% 657
2017
Q3 		$3K Buy
+250
New +$2.46K 0.01% 974

Other funds holding IMDZ

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thompson Davis & Co's IMDZ Position: Q3 2018 in Review

Thompson Davis & Co sold out of Immune Design Corp. (IMDZ) in Q3 2018, closing a stake of 250 shares — an estimated $1K sold.

Thompson Davis & Co first reported a position in IMDZ in Q3 2017 and held it in 4 quarters. The position peaked at $3K in Q3 2017. 71 funds tracked by Wall St. Rank hold IMDZ as of Q3 2018.

  • Thompson Davis & Co reported no remaining Immune Design Corp. position as of Q3 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 250 Immune Design Corp. shares in Q3 2018, an estimated $1K.
  • Thompson Davis & Co first reported a position in Immune Design Corp. in Q3 2017 and held it in 4 quarters.
  • Thompson Davis & Co's Immune Design Corp. position peaked at $3K in Q3 2017.
  • 71 funds tracked by Wall St. Rank held Immune Design Corp. as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.